Předmět: |
|
Zdroj: |
Drug Week; 4/14/2023, p2272-2272, 1p |
Abstrakt: |
Keywords: Avon; United Kingdom; Europe; Brain; Cell Surface Receptors; Central Nervous System; Enzymes and Coenzymes; G-Protein-Coupled Receptor Kinases; G-Protein-Coupled Receptors; Health and Medicine; Intracellular Signaling Peptides and Proteins; Kinase; Locus Coeruleus; Membrane Proteins; Mesencephalon; Neurology; Neuropeptide Receptors; Opiate Receptors; Opioid Receptors; Opioids; Phosphotransferases; Protein-Serine-Threonine Kinases; mu Receptors EN Avon United Kingdom Europe Brain Cell Surface Receptors Central Nervous System Enzymes and Coenzymes G-Protein-Coupled Receptor Kinases G-Protein-Coupled Receptors Health and Medicine Intracellular Signaling Peptides and Proteins Kinase Locus Coeruleus Membrane Proteins Mesencephalon Neurology Neuropeptide Receptors Opiate Receptors Opioid Receptors Opioids Phosphotransferases Protein-Serine-Threonine Kinases mu Receptors 2272 2272 1 04/10/23 20230414 NES 230414 2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on Opioids is the subject of a report. As predicted for a G protein-biased mu agonist, Compound 1 induced minimal agonist-induced internalisation and phosphorylation at intracellular mu receptor serine/threonine residues known to be involved in G protein-coupled receptor kinase (GRK)-mediated desensitisation. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|